Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Glucosidase II

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    95 result(s) found for: Glucosidase II. Displaying page 3 of 5.
    « Previous 1  2  3  4  5  Next»
    EudraCT Number: 2009-011398-33 Sponsor Protocol Number: NN1250-3724 Start Date*: 2010-01-27
    Sponsor Name:Novo Nordisk A/S
    Full Title: BEGIN™: EASY AM A trial comparing efficacy and safety of NN1250 and insulin glargine in subjects with type 2 diabetes
    Medical condition: Type 2 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    12.0 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SK (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-010662-28 Sponsor Protocol Number: NN1250-3672 Start Date*: 2010-01-08
    Sponsor Name:Novo Nordisk A/S
    Full Title: A trial comparing efficacy and safety of NN1250 and insulin glargine in subjects with type 2 diabetes
    Medical condition: type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    12.0 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) FR (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-001712-61 Sponsor Protocol Number: NN5401-3940 Start Date*: 2011-10-28
    Sponsor Name:Novo Nordisk A/S
    Full Title: A 26-week, randomised, open-label, multinational, treat-to-target trial comparing efficacy and safety of insulin degludec/insulin aspart (IDegAsp) twice daily (BID) and BIAsp 30 BID both with metfo...
    Medical condition: Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.0 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BG (Completed) PL (Completed) CZ (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2004-002090-23 Sponsor Protocol Number: K-111-2.02EU Start Date*: 2005-02-03
    Sponsor Name:Kowa Research Europe Ltd.
    Full Title: A phase IIa multicentre randomised double-blind, double-dummy study to evaluate the efficacy and safety of K-111 versus Fenofibrate in patients with hyperlipidaemia.
    Medical condition: Hyperlipidaemia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2017-003219-20 Sponsor Protocol Number: NN9535-4386 Start Date*: 2018-09-13
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effect of semaglutide once-weekly versus insulin aspart three times daily, both as add on to metformin and optimised insulin glargine (U100) in subjects with type 2 diabetes A 52-week, multi-ce...
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) SI (Completed) EE (Completed) BG (Completed) LV (Completed) PL (Completed) GR (Completed) DE (Completed) CZ (Completed) LT (Completed) PT (Completed) ES (Completed) HR (Completed) HU (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2010-022304-50 Sponsor Protocol Number: NN1250-3847 Start Date*: 2011-02-02
    Sponsor Name:Novo Nordisk A/S
    Full Title: A trial comparing the efficacy and safety of insulin degludec three times weekly in insulin naïve subjects with type 2 diabetes mellitus when titrated using two different titration algorithms
    Medical condition: Type 2 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    12.1 10067585 Type 2 diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) HU (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-002462-35 Sponsor Protocol Number: NN5401-1792 Start Date*: 2007-12-05
    Sponsor Name:Novo Nordisk A/S
    Full Title: A 16 week randomised, open labelled, 3-armed, parallel group, treat-to-target trial comparing twice daily (BID) injections of SIAC 30 (B), SIAC 45 (B) and NovoMix® 30, all in combination with metf...
    Medical condition: type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) FI (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-005891-21 Sponsor Protocol Number: I8H-MC-BDCX Start Date*: 2022-08-04
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3, Parallel-Design, Open-Label, Randomized Control Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared to Insulin Degludec in Insulin Naïve Adults with...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2021-002569-16 Sponsor Protocol Number: I8H-MC-BDCU Start Date*: 2022-05-20
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Trial to Evaluate the Efficacy and Safety of LY3209590 Compared with Insulin Degludec in Participants with Type 2 Diabetes Currently ...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) HU (Completed) ES (Ongoing) PL (Completed)
    Trial results: View results
    EudraCT Number: 2009-014894-42 Sponsor Protocol Number: NN304-3785 Start Date*: 2010-08-03
    Sponsor Name:Novo Nordisk A/S
    Full Title: A 26-week randomised, controlled, open label, multicentre, multinational, treat to target trial investigating the impact of dietary intervention on weight change and the relationship between weight...
    Medical condition: Type 2 Diabetes Diabetes mellitus tipo 2
    Disease: Version SOC Term Classification Code Term Level
    12.1 10067585 Type 2 diabetes mellitus LLT
    13 10012602 Diabetes mellitus (incl subtipos) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) SK (Completed) DE (Completed) SI (Completed)
    Trial results: View results
    EudraCT Number: 2012-005793-63 Sponsor Protocol Number: CLIK066A2202 Start Date*: 2013-10-30
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-center, randomized, double-blind, double-dummy, parallel-group dose-finding study to evaluate the change in HbA1c after 12 weeks monotherapy with seven doses of LIK066 compared with placebo...
    Medical condition: Type II Diabetes mellitus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) SK (Prematurely Ended) IT (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-004234-42 Sponsor Protocol Number: NN9535-4650 Start Date*: 2020-03-11
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effect and safety of two different dose-escalation regimens for once-weekly semaglutide s.c. in subjects with type 2 diabetes mellitus previously treated with GLP-1 RAs
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended) AT (Prematurely Ended) SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-005263-97 Sponsor Protocol Number: CS0011-A-U302 Start Date*: 2008-02-28
    Sponsor Name:DAIICHI SANKYO PHARMA DEVELOPMENT
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO AND ACTIVE COMPARATOR-CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF RIVOGLITAZONE AS MONOTHERAPY TREATMENT OF TYPE 2 DIABETES MELLITUS
    Medical condition: The study population is comprised of subjects with a prior diagnosis of type 2 diabetes who are either currently untreated (ie, not receiving antihyperglycemic medication within at least 2 months p...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063624 Type II diabetes mellitus inadequate control LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) LT (Prematurely Ended) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-005047-28 Sponsor Protocol Number: CS0011-A-U301 Start Date*: 2007-03-23
    Sponsor Name:DAIICHI SANKYO PHARMA DEVELOPMENT
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO AND ACTIVE COMPARATOR-CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF RIVOGLITAZONE AS MONOTHERAPY TREATMENT OF TYPE 2 DIABETES MELLITUS
    Medical condition: The current study will support an indication for rivoglitazone as oral monotherapy to improve glycemic control in subjects with type 2 diabetes mellitus not adequately controlled with diet and exer...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063624 Type II diabetes mellitus inadequate control LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) LV (Completed) SK (Completed) AT (Completed) CZ (Completed) GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004047-20 Sponsor Protocol Number: NN1250-4419 Start Date*: 2018-08-28
    Sponsor Name:Novo Nordisk A/S
    Full Title: A randomised, cross-over, open-label, multi-centre trial comparing the effect of insulin degludec and insulin glargine 100U/mL, with or without OADs in subjects with type 2 diabetes using flash glu...
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2006-000796-15 Sponsor Protocol Number: NN1998-1390 Start Date*: 2006-09-11
    Sponsor Name:Novo Nordisk A/S
    Full Title: Inhaled pre-prandial human insulin with the AERx® iDMS plus metformin versus rosiglitazone plus metformin in type 2 diabetes: a 26-week, open-label, multicentre, randomised, parallel trial to inves...
    Medical condition: Type II diabetes
    Disease: Version SOC Term Classification Code Term Level
    8.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Prematurely Ended) ES (Completed) AT (Prematurely Ended) FR (Completed) FI (Prematurely Ended) DE (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-022658-18 Sponsor Protocol Number: CLAF237A23150 Start Date*: 2011-04-11
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 24 weeks treatment with vildagliptin in type 2 diabetes mellitus patients ≥ 70 years (drug-...
    Medical condition: Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    12.1 10067585 Type 2 diabetes mellitus LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) ES (Completed) SK (Completed) DE (Completed) BG (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2006-000924-15 Sponsor Protocol Number: C LF23-0121 06 01 Start Date*: 2006-08-18
    Sponsor Name:FOURNIER Laboratories Ireland Ltd
    Full Title: A randomized, double-blind study comparing the efficacy and safety of a fixed combination of fenofibrate and metformin vs metformin alone in patients with type 2 diabetes mellitus and dyslipidemia ...
    Medical condition: Patients with type 2 diabetes mellitus and dyslipidemia not appropriately controlled with a statin
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) DE (Prematurely Ended) SK (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2016-002801-20 Sponsor Protocol Number: NN1250-4252 Start Date*: 2017-02-10
    Sponsor Name:Novo Nordisk A/S
    Full Title: A trial comparing the efficacy and safety of insulin degludec and insulin glargine 300 units/mL in subjects with type 2 diabetes mellitus inadequately treated with basal insulin with or without ora...
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) DK (Completed) EE (Completed) GR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-002346-20 Sponsor Protocol Number: NN5401-3996 Start Date*: 2012-12-05
    Sponsor Name:Novo Nordisk A/S
    Full Title: A 26-week trial comparing efficacy and safety of insulin degludec/insulin aspart BID and insulin degludec OD plus insulin aspart in subjects with type 2 Diabetes Mellitus treated with basal insulin...
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) NO (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 18 05:08:30 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA